Synapse - Komal Jhaveri

Search Within

Komal Lachhman Jhaveri

Results (202)

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: A United States Electronic Health Records database analysis

Journal Article

Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J. A.; Janni, W.; Jhaveri, K.; Mouabbi, J.; Brufsky, A.; Hamilton, E.; O'Regan, R.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

Journal Article

Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M.
Breast (2025)

Fulltext@MSK | Save

Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: Findings from the SUMMIT basket trial

Journal Article

Goldman, J. W.; Bueno, A. M.; Dooms, C.; Jhaveri, K.; de Miguel, M.; Piha-Paul, S. A.; Unni, N.; Zick, A.; Mahipal, A.; Suga, J. M.; more...
Clinical Lung Cancer (2025)

Fulltext@MSK | Save

Imlunestrant with or without abemaciclib in advanced breast cancer

Journal Article

Jhaveri, K. L.; Neven, P.; Casalnuovo, M. L.; Kim, S. B.; Tokunaga, E.; Aftimos, P.; Saura, C.; O'Shaughnessy, J.; Harbeck, N.; Carey, L. A.; more...
New England Journal of Medicine (2025)

Fulltext@MSK | Save

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study

Journal Article

Bedard, P. L.; Jhaveri, K. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
European Journal of Cancer (2025)

Fulltext@MSK | Save

Abemaciclib in combination with therapies for patients with metastatic breast cancer: A phase 1b study

Journal Article

Tolaney, S. M.; Jhaveri, K.; Helsten, T.; Puhalla, S. L.; Conlin, A.; Dees, E. C.; Beeram, M.; Chapman, S. C.; Lithio, A.; Litchfield, L. M.; more...
Frontiers in Oncology (2025)

Fulltext@MSK | Save

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01

Journal Article

Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas, S.; De Laurentiis, M.; Wang, S.; Martínez Jañez, N.; Borges, G.; Cescon, D. W.; Hattori, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Inavolisib therapy in advanced breast cancer - The authors reply

Correspondence

Turner, N. C.; Thanopoulou, E.; Jhaveri, K. L.
New England Journal of Medicine (2025)

Fulltext@MSK | Save

An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)

Meeting Abstract

George, M.; Frenel, J. S.; Cortés, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)

Meeting Abstract

Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save